Norcross, GA, November 10, 2011 --(PR.com
)-- RayBiotech, Inc., today announced that it has engaged recognized industry expert, David A. Dodd of RiversEdge BioVentures LLC to work with the Company in the areas of Business Development and Strategic Growth Opportunities. This will include the evaluation of enhanced commercial growth opportunities, business development and options for further portfolio expansion. Mr. Dodd will work directly with the team at RayBiotech, while focusing on opportunities to further expand the current highly successful growth and development of the Company.
Commenting on joining with RayBiotech, Mr. Dodd stated, “The team at RayBiotech has established a recognized leadership reputation and brand in the areas of protein and antibody array technologies, resulting in strong double-digit growth and customer expansion. Researchers worldwide depend on the high quality products from RayBiotech as they advance the scientific knowledge that will ultimately improve and enhance peoples’ lives. I look forward to working with this team in further increasing and expanding the RayBiotech contributions and impact to improved knowledge of human biology and, ultimately, better lives.”
Rani Huang, Vice President & Co-Founder of RayBiotech added, “We are extremely pleased to have David join with us in focusing on identifying opportunities to expand our impact and contributions to the field of proteomic research and development. As we continue to develop novel, high quality products and services intended to support improved research, diagnosis and management of improved health, our challenge is to ensure that RayBiotech successfully executes high growth and development strategies on a global basis. We are confident that, with David’s experience and expertise, we will be successful in enhancing the Company’s performance, impact and success.”
About RiversEdge BioVentures LLC
RiversEdge BioVentures LLC (www.riversedgebioventures.com) was formed by David A. Dodd to provide advisory and growth strategies to life science companies worldwide. Believing that there is “always a better way,” Mr. Dodd focuses on identifying, developing and executing actions that result in increased growth and value development. Prior to forming RiversEdge Bioventures Mr. Dodd achieved a distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies. This included the highly recognized transformation of Serologicals Corporation from a company valued at approximately $80 million in June 2000 to the $1.5 billion all-cash sale to Millipore Corporation in July 2006. In addition, Mr. Dodd has served and continues to serve as CEO, Chairman and Board Member at several successful life science companies.
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) introduced the first commercially available cytokine antibody array in 2001. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).